Press release
Microsatellite Stable Colorectal Cancer Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2032, DelveInsight
Unlock key insights into the Microsatellite Stable Colorectal Cancer Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Microsatellite Stable Colorectal Cancer Therapeutics Market Outlook [https://www.delveinsight.com/sample-request/microsatellite-stable-colorectal-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Microsatellite Stable Colorectal Cancer Market Report
* Approximately 85 percent of instances of non-metastatic colorectal cancer (CRC) are associated with chromosomal instability and a proficient DNA Mismatch-Repair mechanism (pMMR); these cases are also known as CRC with microsatellite stability (MSS).
* In the United States, an estimated 104,610 new cases of colon cancer and 43,340 cases of rectal cancer will be diagnosed in 2020
* Men have a 30% greater CRC incidence rate than women.
* In their lifetime, around 4.4 percent of males (1 in 23) and 4.1 percent of women (1 in 25) will be diagnosed with CRC. Lifetime risk is equivalent in men and women, despite greater incidence rates in males because of women's longer life expectancy.
* The relative survival rate for Colorectal cancer is 64 percent after 5 years of diagnosis and 58 percent after 10 years of diagnosis.
* The increase in Microsatellite Stable Colorectal Cancer Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
* As per DelveInsight analysis, the Microsatellite Stable Colorectal Cancer Market is anticipated to witness growth at a considerable CAGR.
* The leading Microsatellite Stable Colorectal Cancer Companies such as Gritstone Oncology, Merck Sharp & Dohme Corp, Arrys Therapeutics, NeoImmuneTec and others.
* Promising Microsatellite Stable Colorectal Cancer Pipeline Therapies such as Lenvatinib, Pembrolizumab (KEYTRUDA Registered ), GI-101, Docetaxel, BMS-986340, Nivolumab, FOG-001, Balstilimab, Botensilimab and others.
Stay ahead in the competitive landscape of the Microsatellite Stable Colorectal Cancer Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Microsatellite Stable Colorectal Cancer Treatment Market Size [https://www.delveinsight.com/sample-request/microsatellite-stable-colorectal-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Microsatellite Stable Colorectal Cancer Epidemiology Segmentation in the 7MM
The epidemiology section of Microsatellite Stable Colorectal Cancer offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.
Download the report to understand which factors are driving Microsatellite Stable Colorectal Cancer epidemiology trends @ Microsatellite Stable Colorectal Cancer Prevalence [https://www.delveinsight.com/sample-request/microsatellite-stable-colorectal-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Microsatellite Stable Colorectal Cancer Drugs Market
The Microsatellite Stable Colorectal Cancer Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Microsatellite Stable Colorectal Cancer signaling in Microsatellite Stable Colorectal Cancer are likely to uncover new therapeutic targets and further expand treatment options for patients.
Microsatellite Stable Colorectal Cancer Treatment Market Landscape
The Microsatellite Stable Colorectal Cancer treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Microsatellite Stable Colorectal Cancer has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.
To learn more about Microsatellite Stable Colorectal Cancer treatment guidelines, visit @ Microsatellite Stable Colorectal Cancer Market Drivers and Barriers [https://www.delveinsight.com/sample-request/microsatellite-stable-colorectal-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Microsatellite Stable Colorectal Cancer Companies
Gritstone Oncology, Merck Sharp & Dohme Corp, Arrys Therapeutics, NeoImmuneTec and others.
Microsatellite Stable Colorectal Cancer Market Outlook
The report's outlook on the Microsatellite Stable Colorectal Cancer market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Microsatellite Stable Colorectal Cancer therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Microsatellite Stable Colorectal Cancer drug and late-stage pipeline therapy.
Microsatellite Stable Colorectal Cancer Drugs Uptake
The drug chapter of the Microsatellite Stable Colorectal Cancer report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Microsatellite Stable Colorectal Cancer.
Explore the dynamics of the Microsatellite Stable Colorectal Cancer Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Microsatellite Stable Colorectal Cancer Ongoing Clinical Trials Analysis [https://www.delveinsight.com/sample-request/microsatellite-stable-colorectal-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Microsatellite Stable Colorectal Cancer Market Report
* Coverage- 7MM
* Study Period- 2019-2032
* Microsatellite Stable Colorectal Cancer Companies- Gritstone Oncology, Merck Sharp & Dohme Corp, Arrys Therapeutics, NeoImmuneTec, and others.
* Microsatellite Stable Colorectal Cancer Pipeline Therapies- Lenvatinib, Pembrolizumab (KEYTRUDA Registered ), GI-101, Docetaxel, BMS-986340, Nivolumab, FOG-001, Balstilimab, Botensilimab and others.
* Microsatellite Stable Colorectal Cancer Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
* Microsatellite Stable Colorectal Cancer Unmet Needs, KOL's views, Analyst's views, Microsatellite Stable Colorectal Cancer Market Access and Reimbursement
Table of Contents
1. Key Insights
2. Executive Summary of Microsatellite Stable Colorectal Cancer
3. Competitive Intelligence Analysis for Microsatellite Stable Colorectal Cancer
4. Microsatellite Stable Colorectal Cancer: Market Overview at a Glance
5. Microsatellite Stable Colorectal Cancer: Disease Background and Overview
6. Microsatellite Stable Colorectal Cancer Patient Journey
7. Microsatellite Stable Colorectal Cancer Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Microsatellite Stable Colorectal Cancer Unmet Needs
10. Key Endpoints of Microsatellite Stable Colorectal Cancer Treatment
11. Microsatellite Stable Colorectal Cancer Marketed Products
12. Microsatellite Stable Colorectal Cancer Emerging Therapies
13. Microsatellite Stable Colorectal Cancer: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Microsatellite Stable Colorectal Cancer Market Outlook
16. Access and Reimbursement Overview of Microsatellite Stable Colorectal Cancer
17. Microsatellite Stable Colorectal Cancer KOL Views
18. Microsatellite Stable Colorectal Cancer Market Drivers
19. Microsatellite Stable Colorectal Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=microsatellite-stable-colorectal-cancer-therapeutics-market-size-in-7mm-is-expected-to-grow-at-a-decent-cagr-by-2032-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/microsatellite-stable-colorectal-cancer-market
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Microsatellite Stable Colorectal Cancer Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2032, DelveInsight here
News-ID: 4176522 • Views: …
More Releases from ABNewswire
Metastatic Colorectal Cancer Pipeline Outlook 2025: Insights Into Therapies, Res …
DelveInsight's, "Metastatic Colorectal Cancer Pipeline Insight 2025" report provides comprehensive insights about 150+ companies and 180+ pipeline drugs in Metastatic Colorectal Cancer pipeline landscape. It covers the Metastatic Colorectal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Colorectal Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Metastatic Colorectal Cancer pipeline products in this…
C-MET NSCLC Pipeline Outlook 2025: Insights Into Therapies, Research, and Market …
DelveInsight's "C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the C-MET Non-Small Cell Lung Cancer pipeline landscape. It covers the C-MET+ NSCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the C-MET+ NSCLC therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products…
PD-1+ NSCLC Pipeline Outlook 2025: Insights Into Therapies, Research, and Market …
DelveInsight's, "PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline Insight 2025" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the PD-1+ NSCLC pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products…
EGFR + NSCLC Pipeline Outlook 2025: Insights Into Therapies, Research, and Marke …
DelveInsight's, "EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Insight 2025" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) pipeline landscape. It covers the EGFR + NSCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive…
More Releases for Colorectal
Metastatic Colorectal Cancer Therapeutics Market - Innovation in Motion: Elevate …
Newark, New Castle, USA: The "Metastatic Colorectal Cancer Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Metastatic Colorectal Cancer Therapeutics Market: https://www.growthplusreports.com/report/metastatic-colorectal-cancer-therapeutics-market/8685
This latest report researches the…
Potential Opportunities of Colorectal Cancer Therapeutics Market
The global colorectal cancer therapeutics market size is projected to reach USD 16.58 billion by 2026, owing to the rise in the prevalence of colorectal cancer worldwide. A report by Fortune Business Insights(TM) titled, "Colorectal Cancer Therapeutics Market Size, Share & Industry Analysis, By Therapy (Targeted Therapy, Immunotherapy, Chemotherapy, Others), By Cancer Type (Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors, Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and…
Colorectal Cancer Pipeline Therapeutic Review H1 2017
Colorectal Cancer Pipeline Review H1 2017 provides an overview of the Colorectal Cancer (Oncology) pipeline landscape. Colorectal cancer is cancer that starts in the large intestine (Colorectal). There is no single cause of colorectal cancer. Nearly all colorectal cancers begin as noncancerous (benign) polyps, which slowly develop into cancer.
For More on Colorectal Cancer Pipeline Review H1 2017 Report Inquire @
https://goo.gl/1HQ4Fn .
Report Description:
Pharmaceutical guide Colorectal Cancer - Pipeline Review H1…
US Colorectal Cancer Drug Pipeline Analysis
Among all the regions affected with colorectal cancer, the US would continue to account for a giant’s share owing to its huge population base. With regards to rates of increase, it is most likely that the US would witness a modest increase in the prevalence of the disease, mostly as a result of the country having already reached epidemic proportions of the disease. According to estimates, approximately 55,000 people die…
Colorectal Cancer - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Colorectal Cancer - Heat Map and Analysis to its growing collection of premium market research reports.
Colorectal cancer (CRC), otherwise known as bowel cancer, is a malignancy originating in the colon (the large intestine) or rectum, both of which are located towards the end of the human gastrointestinal tract. It begins as a benign tumor, which is almost always in…
Colorectal Cancer Treatment Market- Global Outlook 2024
Colorectal cancer is cancer that starts in the colon or rectum. The colon and the rectum are parts of the large intestine, which is the lower part of the body’s digestive system. The colon absorbs water and nutrients from the food and stores waste matter (stool). Stool moves from the colon into the rectum before it leaves the body. Colorectal cancer often begins as a growth called a polyp, which…
